Stockholders' Equity and Noncontrolling Interests - Stock-Based Compensation Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Stock Appreciation Rights
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Beginning balance (in shares)	66
Forfeited (in shares)	0
Ending balance (in shares)	66
Weighted-Average Grant Date Fair Value, Beginning balance (in dollars per share)	$ 110.83
Weighted-Average Grant Date Fair Value, Expired (in dollars per share)	0
Weighted-Average Grant Date Fair Value, Ending balance (in dollars per share)	$ 110.83
Weighted-average contractual remaining life (in years)	1 month 2 days
Exercisable shares (in shares)	66
Weighted-average exercise price (in dollars per share)	$ 110.83
Weighted-average exercise price exercisable shares (in dollars per share)	$ 110.83
Compensation expense (credit)	$ (1,000)	$ (2,000)
Fair value of liability award	$ 0		$ 1,000
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Beginning balance (in shares)	10,000
Ending balance (in shares)	10,000
Weighted-Average Grant Date Fair Value, Beginning balance (in dollars per share)	$ 80.05
Weighted-Average Grant Date Fair Value, Ending balance (in dollars per share)	$ 80.05
Weighted-average contractual remaining life (in years)	2 years 11 months 1 day
Weighted-average exercise price (in dollars per share)	$ 80.05
Compensation expense (credit)	$ 20,000	20,000
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Beginning balance (in shares)	8,250
Granted (in shares)	0
Exercised (in shares)	0
Ending balance (in shares)	8,250
Weighted-Average Grant Date Fair Value, Beginning balance (in dollars per share)	$ 113.19
Weighted-Average Grant Date Fair Value, Granted (in dollars per share)	0
Weighted-Average Grant Date Fair Value, Exercised (in dollars per share)	0
Weighted-Average Grant Date Fair Value, Ending balance (in dollars per share)	$ 113.19
Weighted-average contractual remaining life (in years)	29 days
Weighted-average exercise price (in dollars per share)	$ 113.19
Compensation expense (credit)	$ (171,000)	$ 363,000
Fair value of liability award	$ 680,000		$ 971,000